SCHEMBL187083

SCHEMBL187083

NC1(CO)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL365342 0.96
SCHEMBL229077 0.86
SCHEMBL534445 0.86
SCHEMBL25170089 0.85 EPHX1 (0.31)
SCHEMBL1151339 0.83 TSHR (0.36)
SCHEMBL1150689 0.83 TSHR (0.36)
Hydrochloric Acid SCHEMBL18208089 0.83
SCHEMBL1117542 0.83 TSHR (0.36)
SCHEMBL373389 0.83
SCHEMBL1150757 0.83 TSHR (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 766 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4378936-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER Hinova Pharmaceuticals Inc. (CN) 2024-06-05 EP claimed
CN-115084519-B Lithium iron phosphate system slurry and preparation method and application thereof 蜂巢能源科技(无锡)有限公司 2024-02-09 CN claimed
CN-116730972-A Crown ether supermolecular compound with phase change characteristic and preparation method thereof 东南大学 2023-09-12 CN claimed
CN-115677667-A Bifunctional chimera heterocyclic compound and application thereof as androgen receptor degrading agent 海创药业股份有限公司 2023-02-03 CN claimed
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 US claimed
US-20210060040-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-03-04 US claimed
US-10632134-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2020-04-28 US claimed
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2020-03-12 US claimed
CN-110709085-A Compounds and methods for treating visceral pain 艾尼纳制药公司 2020-01-17 CN claimed
CN-109970708-A Cannibinoid receptor modulators 艾尼纳制药公司 2019-07-05 CN claimed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US claimed
EP-2678318-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2014-01-01 EP claimed
WO-2013130660-A1 AMIDES AS PIM INHIBITORS AMGEN INC. (US) 2013-09-06 WO claimed
EP-2408739-B1 A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF EOS ETHICAL ONCOLOGY SCIENCE SPA IN ABBREVIATED FORM EOS SPA (IT) 2013-08-14 EP claimed
EP-2626073-A1 Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4) Harmonic Pharma (FR) 2013-08-14 EP claimed
EP-2592070-A2 Tetrazole-substituted arylamides F. Hoffmann-La Roche AG (CH) 2013-05-15 EP claimed
WO-2012116279-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2012-08-30 WO claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 US claimed
CN-102356063-A Method for preparing 6- (7- ((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -N-methyl-1-naphthamide and synthetic intermediate thereof EOS ETHICAL ONCOLOGY SCIENCE SPA IN ABBREVIATED FORM EOS SPA (IT) 2012-02-15 CN claimed
US-20120010415-A1 PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF CLOVIS ONCOLOGY ITALY S.R.L. (IT) 2012-01-12 US claimed